FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161055573> ?p ?o ?g. }

• W2161055573 endingPage "564" @default.
• W2161055573 startingPage "555" @default.
• W2161055573 abstract "Background:Opioids may alleviate chronic neuropathic pain (NP), but are considered second/third-line analgesia due to their poor gastrointestinal (GI) tolerability. A fixed combination of prolonged-release oxycodone and naloxone (OXN) has been developed to overcome the GI effects. The aim of this analysis was to evaluate analgesic effectiveness and tolerability of low-dose OXN in patients with moderate-to-severe noncancer NP despite analgesia.Methods:This retrospective observation of consecutive adult patients, treated open-label for 8 weeks at a single Italian centre, evaluated effectiveness (pain intensity numerical rating scale [NRS], Patients’ Global Impression of Change [PGIC], Douleur Neuropathique 4 inventory [DN4] and Chronic Pain Sleep Inventory [CPSI]), doses of daily OXN and adjuvant medication, rescue paracetamol use, bowel function index (BFI), laxative use, and safety.Results:Of 200 patients (mean age 65.9 years; 54% female) with NP included in the analysis; 97% completed 8 weeks’ treatment. At the observation start, all patients were taking anticonvulsants and complained of constipation, and 60% were receiving opioids. Pain intensity and DN4 score decreased significantly by endpoint (NRS p < 0.0001; DN4 p < 0.0001) and need for rescue analgesics abated. Reduction in pain intensity throughout the observation was similar regardless of NP aetiology. According to PGIC, 87.8% of patients were much/extremely improved, CPSI (p < 0.0001) and BFI were significantly improved (p < 0.0001) and laxative use decreased. No differences were found between patients <65 years vs those ≥65 years. OXN was generally well tolerated.Study limitations:Study limitations including the retrospective observational design, the lack of a control group and the single-centre design may limit the generalizability of our findings.Conclusions:Low-dose OXN (25.0 ± 12.5 mg/day) added to anticonvulsants was highly effective in controlling noncancer NP of varied aetiology, with reduced need for rescue analgesia and improved quality of sleep, and was well tolerated, with improved bowel function and reduced laxative use. The efficacy and tolerability of OXN demonstrated in this real-world setting suggest its utility in this difficult to manage patient population." @default.
• W2161055573 created "2016-06-24" @default.
• W2161055573 creator A5015263832 @default.
• W2161055573 creator A5020587879 @default.
• W2161055573 creator A5053780572 @default.
• W2161055573 creator A5055491592 @default.
• W2161055573 creator A5070205249 @default.
• W2161055573 creator A5079716431 @default.
• W2161055573 creator A5081314726 @default.
• W2161055573 date "2013-12-05" @default.
• W2161055573 modified "2023-09-27" @default.
• W2161055573 title "Effectiveness and tolerability of low-dose oral oxycodone/naloxone added to anticonvulsant therapy for noncancer neuropathic pain: an observational analysis" @default.
• W2161055573 cites W134906642 @default.
• W2161055573 cites W1490240620 @default.
• W2161055573 cites W1493383013 @default.
• W2161055573 cites W1606572296 @default.
• W2161055573 cites W1735400496 @default.
• W2161055573 cites W1966998000 @default.
• W2161055573 cites W1967871273 @default.
• W2161055573 cites W1967949552 @default.
• W2161055573 cites W1979844313 @default.
• W2161055573 cites W1981120831 @default.
• W2161055573 cites W1982683778 @default.
• W2161055573 cites W1990014844 @default.
• W2161055573 cites W1996926116 @default.
• W2161055573 cites W1997328578 @default.
• W2161055573 cites W2020500184 @default.
• W2161055573 cites W2027886849 @default.
• W2161055573 cites W2035629884 @default.
• W2161055573 cites W2041137967 @default.
• W2161055573 cites W2056362045 @default.
• W2161055573 cites W2060416618 @default.
• W2161055573 cites W2060855217 @default.
• W2161055573 cites W2063340902 @default.
• W2161055573 cites W2063414861 @default.
• W2161055573 cites W2063671307 @default.
• W2161055573 cites W2066553562 @default.
• W2161055573 cites W2066829799 @default.
• W2161055573 cites W2078115636 @default.
• W2161055573 cites W2079038140 @default.
• W2161055573 cites W2088221066 @default.
• W2161055573 cites W2088600148 @default.
• W2161055573 cites W2089433968 @default.
• W2161055573 cites W2090637590 @default.
• W2161055573 cites W2122756722 @default.
• W2161055573 cites W2128412489 @default.
• W2161055573 cites W2128848460 @default.
• W2161055573 cites W2136546388 @default.
• W2161055573 cites W2136743000 @default.
• W2161055573 cites W2147212130 @default.
• W2161055573 cites W2148950301 @default.
• W2161055573 cites W2150884903 @default.
• W2161055573 cites W2152953447 @default.
• W2161055573 cites W2155412494 @default.
• W2161055573 cites W2156266538 @default.
• W2161055573 cites W2163255559 @default.
• W2161055573 cites W2164513741 @default.
• W2161055573 cites W2169071518 @default.
• W2161055573 cites W2171516791 @default.
• W2161055573 cites W2411289564 @default.
• W2161055573 cites W2418058242 @default.
• W2161055573 cites W2749067245 @default.
• W2161055573 cites W3090293687 @default.
• W2161055573 cites W35111923 @default.
• W2161055573 cites W77425707 @default.
• W2161055573 cites W2127906114 @default.
• W2161055573 doi "https://doi.org/10.1185/03007995.2013.866545" @default.
• W2161055573 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24251879" @default.
• W2161055573 hasPublicationYear "2013" @default.
• W2161055573 type Work @default.
• W2161055573 sameAs 2161055573 @default.
• W2161055573 citedByCount "11" @default.
• W2161055573 countsByYear W21610555732014 @default.
• W2161055573 countsByYear W21610555732015 @default.
• W2161055573 countsByYear W21610555732016 @default.
• W2161055573 countsByYear W21610555732017 @default.
• W2161055573 countsByYear W21610555732021 @default.
• W2161055573 crossrefType "journal-article" @default.
• W2161055573 hasAuthorship W2161055573A5015263832 @default.
• W2161055573 hasAuthorship W2161055573A5020587879 @default.
• W2161055573 hasAuthorship W2161055573A5053780572 @default.
• W2161055573 hasAuthorship W2161055573A5055491592 @default.
• W2161055573 hasAuthorship W2161055573A5070205249 @default.
• W2161055573 hasAuthorship W2161055573A5079716431 @default.
• W2161055573 hasAuthorship W2161055573A5081314726 @default.
• W2161055573 hasBestOaLocation W21610555732 @default.
• W2161055573 hasConcept C126322002 @default.
• W2161055573 hasConcept C170493617 @default.
• W2161055573 hasConcept C197934379 @default.
• W2161055573 hasConcept C2776029756 @default.
• W2161055573 hasConcept C2776468701 @default.
• W2161055573 hasConcept C2777107010 @default.
• W2161055573 hasConcept C2778375690 @default.
• W2161055573 hasConcept C2780661987 @default.
• W2161055573 hasConcept C2780820201 @default.
• W2161055573 hasConcept C2781063702 @default.
• W2161055573 hasConcept C2781112942 @default.
• W2161055573 hasConcept C42219234 @default.

• next